Table 1 Sham-acupuncture related items recommended in both STRICTA 2010 and TIDieR-placebo
Items in STRICTA 2010 | Items in TIDieR-placebo | Proportion | |
|---|---|---|---|
Acupuncture rationale | (1a) Style of acupuncture (e.g., Traditional Chinese Medicine, Japanese, Korean, Western medical, Five Element, ear acupuncture, etc.) | NR | |
(1b) Reasoning for treatment provided, based on historical context, literature sources and/or consensus methods, with references where appropriate | 2.Why: Describe any rationale, theory, or goal of the elements essential to the placebo/ sham intervention | 49.4% | |
(1c) Extent to which treatment was varied | 9.Tailoring: If the placebo/sham intervention was planned to be personalised, titrated, or adapted, then describe what, why, when, and how | 4.9% | |
Details of needling | 2a) Number of needle insertions per subject per session (mean and range where relevant) | 4. What (Procedure): Describe each of the procedures, activities, and/or processes used in the placebo/sham intervention, including any enabling or support activities | 53.7% |
2b) Names (or location if no standard name) of points used (uni/bilateral) | 90.0% | ||
2c) Depth of insertion, based on a specified unit of measurement, or on a particular tissue level | 39.7% | ||
2d) Response sought (e.g. de qi or muscle twitch response) | 20.6% | ||
2e) Needle stimulation (e.g. manual, electrical) | 41.5% | ||
2f) Needle retention time | 65.4% | ||
2 g) Needle type (diameter, length, and manufacturer or material) | 3.What (materials): Describe any physical or informational materials used in the placebo/sham intervention, including those provided to participants or used in intervention delivery or in training of intervention providers. Provide information on where the materials can be accessed (such as an online appendix, URL) | 93.9%(type) | |
44.3%(size) | |||
14.4%(assisting tools) | |||
37.9%(manufacturer) | |||
Treatment regimen | (3a) Number of treatment sessions | 8.When and how much: Describe the number of times the placebo/sham intervention was delivered and over what period of time, including the number of sessions, their schedule, and their duration, intensity, or dose. If relevant, include the duration of the pre- and postrandomisation consultations | 77.8% |
(3b) Frequency and duration of treatment sessions | 75.9% | ||
78.0% | |||